NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Ramp Corporation today announced that its HealthRamp subsidiary has executed an agreement with Novo Nordisk under which HealthRamp’s CarePoint, point-of- prescribing technologies will be deployed to a targeted group of physicians. Novo Nordisk is the second company to enter HealthRamp’s successful CarePoint Companion program, building on the past year’s successful deployment of CarePoint’s Companion program to psychiatrists in New York. Novo Nordisk is a healthcare company and a world leader in diabetes care with the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. Ramp Corporation, through its wholly owned HealthRamp subsidiary, markets the CarePoint technology suite. CarePoint enables electronic prescribing, lab orders and results, Internet-based communication, data integration, and transaction processing over a handheld device or browser, at the point-of-care.
Under the agreement, HealthRamp will be paid to deploy its CarePoint Companion program to selected physicians. HealthRamp’s patent-pending Companion technology is intended to provide total marketing content management for the pharmaceutical industry. Companion delivers electronic detailing, intelligent messaging and valuable point-of-care information, enabling pharmaceutical companies to make their detailing sales force more effective, monitor feedback from physicians in real-time, and much more. Intelligent messaging provides interaction with physicians, never before possible, based on patient-specific demographics, utilizing a discreet and HIPAA-compliant approach. Companion will also give pharmaceutical companies the ability to track sampling data in real-time and receive electronic reorder requests for samples directly from the individual physician.
“HealthRamp’s CarePoint Companion program has proven its value to pharmaceutical companies in fostering relationships with the physician community. We are excited to announce today’s agreement with Novo Nordisk, as it is our first commercial agreement for CarePoint’s Companion technology. Utilizing Companion, we are able to provide FDA-approved messages and other valuable information at the point-of-prescribing to a targeted physician population. As we expand the distribution of our healthcare connectivity technologies, the CarePoint Companion program becomes an increasingly attractive means for pharmaceutical companies, health plans and other companies to interact with physicians,” stated Andrew Brown, Ramp CEO and President. “We are committed to serving our physician users first and foremost, and with our CarePoint Companion program we are able to greatly increase the effectiveness and efficiency of their communications with those companies that they interact with on a daily basis,” concluded Brown.
Ramp Corporation, through its wholly owned HealthRamp subsidiary, markets the CarePoint and CareGiver technology suites. CarePoint enables electronic prescribing, lab orders and results, Internet-based communication, data integration, and transaction processing over a handheld device or browser, at the point-of-care. CareGiver allows long term care facility staff to easily place orders for drugs, treatments and supplies from a wireless handheld PDA or desktop Internet web browser. HealthRamp’s products enable communication of high value-added healthcare information among physician offices, pharmacies, hospitals, pharmacy benefit managers, health management organizations, pharmaceutical companies and health insurance companies. Additional information about Ramp, and its products and services, can be found at http://www.ramp.com/.
Safe Harbor Statement: To the extent that any statements made in this press
release contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by
the use of words such as “expects,” “plans,” “will,” “may,” “anticipates,”
“believes,” “should,” “intends,” “estimates,” and other words of similar meaning. These statements are subject to risks and uncertainties that cannot
be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, the ability of the
Company to raise capital to finance the development of its Internet services
and related software, the effectiveness, profitability and the marketability
of those services, the ability of the Company to protect its proprietary
information and to retain and expand its user base, the establishment of an efficient corporate operating structure as the Company grows and, other risks
detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Ramp Corporation
CONTACT: Andrew Brown of Ramp Corporation, +1-212-440-1548
Web site: http://www.ramp.com/
